Pharmascience Faces Six-Year Wait On Canadian Invega Sustenna
Key Canadian Patent Not Obvious And Is Patentable Subject Matter
Pharmascience has failed in a two-pronged validity challenge to a key patent shielding Janssen’s Invega Sustenna treatment for schizophrenia.
